Scynexis, Inc. – Mucocutaneous Candidiasis

Access Program Information

This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy
and safety of SCY-078 in patients ≥ 18 years of age with a documented fungal disease that has
been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

Rare Disease: